Browse the corpus

Eastern equine encephalitis (EEE) is one of the most severe arboviral infections in the Americas, with a case-fatality rate of approximately 30% and significant long-term neurologic sequelae in survivors. The disease is caused by Eastern equine encephalitis virus (EEEV), an RNA virus maintained in a mosquito-bird enzootic cycle, with occasional spillover to humans and other mammals. In the United States, cases are rare but increasing in geographic distribution, primarily occurring from May to October in states including Florida, Georgia, Maryland, Wisconsin, and New Jersey. This course reviews the presentation of EEEV, with most infections being asymptomatic, but a small proportion progress to encephalitis, presenting with fever, headache, altered mental status, and seizures. The diagnosis of EEE, involving serial serologic testing and neuroimaging, and its primarily supportive management, are also discussed, highlighting the importance of prevention through vector control and personal protective measures. Participants will gain an in-depth knowledge of the epidemiology, risk factors, clinical presentation, and diagnostic strategies for this emerging arboviral infection, as well as best practices in supportive care and monitoring for neurologic complications. Clinicians will also learn to interpret laboratory and imaging findings, apply infection prevention strategies, and engage in patient-centered education to reduce exposure risks. This activity for healthcare professionals is designed to enhance the learner's competence in identifying EEE, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition to improve patient outcomes of severe arboviral encephalitides. Objectives: Identify the clinical features that distinguish Eastern equine encephalitis from other causes of meningoencephalitis. Apply diagnostic testing, including molecular and serologic methods, to confirm Eastern equine encephalitis virus infection. Evaluate evidence-based strategies for management of Eastern equine encephalitis in diverse populations. Collaborate management strategies effectively with interprofessional team members to improve coordinated care and outcomes in patients with Eastern equine encephalitis. Access free multiple choice questions on this topic.

Eastern equine encephalitis (EEE) ranks among the most severe arboviral encephalitides in the Americas. Classified as an emerging infection, reports indicate a gradual increase in incidence alongside an expanding geographic distribution. In the United States, 6 to 8 cases occur annually, predominantly from May through October, with the highest concentrations reported in Florida, Georgia, Maryland, Wisconsin, and New Jersey.[1][2][CDC. Eastern Equine Encephalitis, Historical Data. June 3, 2025] Eastern equine encephalitis virus (EEEV) also represents a potential bioterrorism threat due to its capability for aerosol transmission.[3] The disease exhibits a case-fatality rate of approximately 30%, while more than half of survivors experience substantial long-term neurologic sequelae.[2]

Eastern equine encephalitis virus (EEEV), the causative agent, is a single-stranded RNA arbovirus belonging to the Togaviridae family, genus Alphavirus. The virus persists in nature through an enzootic cycle involving passerine birds and its primary vector, Culiseta melanura mosquitoes, which typically inhabit freshwater hardwood swamps. Recent evidence indicates that additional mosquito species, including Coquillettidia perturbans, Aedes cinereus, and Aedes canadensis, contribute to EEEV transmission.[4] Mosquitoes acquire the virus during blood meals from passerine birds and, in turn, may incidentally transmit it to a range of vertebrate hosts, including mammals, reptiles, and amphibians. Occasionally, the virus extends beyond this enzootic cycle to infect dead-end hosts, eg, humans, swine, equids, and pheasants. Humans qualify as dead-end hosts because viremia levels remain too low to sustain transmission back to mosquitoes. Cross-species transmission occurs sporadically, with climatic changes and global warming likely contributing to the rising incidence of cases. Other factors influencing transmission dynamics include environmental disturbances, migratory bird patterns, and human activities that increase exposure to vector habitats.[5] In 2017, EEEV transmission was documented for the first time via organ transplantation.[6][7]

The first recognized human cases of EEEV occurred during a Massachusetts outbreak in 1938. Since then, infections have been reported sporadically along the Atlantic and Gulf coasts, where ecological conditions support enzootic transmission. A landmark outbreak in 1959 in New Jersey produced 32 cases within 8 weeks, while in 2019, 38 cases marked the highest annual incidence in the past 2 decades.[CDC. Eastern Equine Encephalitis, Historical Data. June 3, 2025] Since 2003, EEE has been a nationally notifiable disease and is monitored through ArboNET, the national arboviral surveillance system. To date, cases have been documented in 20 states, with Massachusetts, Florida, Michigan, and New Hampshire reporting the highest numbers nationwide. The annual mean incidence is approximately 11 cases, with neuroinvasive disease occurring twice as often in males. Incidence exhibits a bimodal distribution, with the highest risk observed among children younger than 5, adults older than 60, and immunocompromised individuals.[8] Additional high-risk groups include those living in or visiting endemic forested areas near swamps or marshes, and individuals with outdoor occupational (eg, agriculture) or recreational (eg, camping and gardening) exposures.[9] Recent data indicate that the case-fatality rate for EEEV ranges between 30% and 40%, with nearly half of survivors experiencing long-term neurologic sequelae. Notably, ArboNET data reveal substantially more non-human than human activity, likely reflecting ecological barriers to EEEV spillover from enzootic to epizootic cycles, as well as limitations in surveillance and diagnostic testing.[10]

Following the bite of an infected mosquito, EEEV enters the skin and targets dendritic and Langerhans cells. These antigen-presenting cells migrate to regional lymphoid tissue, promoting viral replication and subsequent viremia. The virus then spreads systemically and invades the central nervous system through the bloodstream or peripheral nerves. Within the central nervous system, EEEV triggers a pronounced neuroinflammatory response characterized by activation of microglia and astrocytes, release of proinflammatory cytokines, eg, IL-6 and TNF-α, disruption of blood–brain barrier integrity, and widespread neuronal injury. The incubation period typically spans 4 to 10 days before clinical symptoms manifest.[11][5]

Experimental and clinical studies have demonstrated the mesenchymal cell tropism of EEEV, with early viral replication documented in bone, tendon, and myocardial tissue. In addition, involvement of the lungs, stomach, kidneys, and spleen has been reported in systemic infection.[6] Neuropathologic findings are generally nonspecific and overlap with other viral encephalitides, most commonly showing perivascular lymphohistiocytic cuffing. Additional features may include leptomeningeal vascular congestion, hemorrhage, encephalomalacia, and, in rare instances, pyogenic meningeal exudates.[12][13] Detection of viral antigen within affected tissues can be achieved by immunohistochemical staining.[14] A case report from Duke University described optic nerve pathology mirroring cerebral changes in a fatal human infection.[12] Some authors have also reported focal infiltration of neutrophils and macrophages in the brain parenchyma, leading to neuronal destruction, focal necrosis, and local demyelination with the formation of glial nodules. In patients who succumbed later in the disease course, cortical atrophy has been documented at autopsy.[13]

Symptomatic arboviral infections in humans can be broadly categorized into 3 clinical syndromes: febrile systemic illness, exemplified by uncomplicated dengue fever; hemorrhagic fever, as seen in dengue hemorrhagic fever and yellow fever; and encephalitis, which encompasses EEE, Venezuelan equine encephalitis, Japanese encephalitis, and La Crosse encephalitis. Approximately 96% of individuals infected with EEEV remain asymptomatic. Among those who develop illness, the initial presentation is typically nonspecific, characterized by fever, headache, malaise, chills, arthralgias, nausea, and vomiting.[5] Fewer than 5% of infected individuals progress to meningitis or encephalitis. Neurologic symptoms usually emerge within the first 5 days and are clinically indistinguishable from other viral encephalitides. Altered mental status and seizures are the most frequent findings, although paresthesias and focal weakness have also been reported.[5][13] Several studies have highlighted the prognostic value of the prodromal phase. A brief prodrome is associated with higher rates of mortality or severe neurologic sequelae, whereas a more prolonged, mild-to-moderate prodrome is more often linked to survival with moderate disability or full recovery, particularly in pediatric patients.[5] Risk factors for poor neurologic outcomes include hyponatremia, diffuse and symmetric abnormalities on neuroimaging, severe functional impairment at presentation, markedly depressed brain activity on electroencephalography, and underlying immunosuppression.[9]

Basic laboratory findings in EEE may include peripheral leukocytosis. Cerebrospinal fluid (CSF) analysis typically demonstrates pleocytosis that is initially neutrophilic and later transitions to a lymphocytic predominance, accompanied by elevated protein and normal glucose concentrations.[9][6] Specific diagnostic assays, including polymerase chain reaction (PCR) of blood or CSF and serologic testing, may have a negative result early in the illness but often become positive within the first week, when neurologic injury has already occurred.[5] Current recommendations emphasize obtaining repeated serum samples in patients with encephalitis and a high index of suspicion for viral etiology, since antibody titers can rise 4-fold within several days. Moreover, a positive serum antibody result should not be disregarded in the setting of negative CSF nucleic acid testing, particularly early in the disease course. When a lumbar puncture cannot be repeated, serial serologic testing may support a definitive diagnosis.[15] Additionally, both antibody- and nucleic acid–based methods are valuable, although molecular testing may be particularly useful in immunocompromised patients with impaired antibody production.[8] Available modalities include enzyme-linked immunosorbent assay (ELISA) and indirect fluorescent antibody (IFA) testing.[16] Neuroimaging findings typically involve the basal ganglia, thalami, and cerebral cortex. Magnetic resonance imaging (MRI), particularly T2-weighted and FLAIR sequences, often demonstrates focal lesions without marked edema, a contrast to common autopsy findings of severe cerebral edema that peak around day 12 in up to 60% of fatal cases. In pediatric patients, cortical involvement appears to predominate.[13] Early thalamic and basal ganglia involvement on MRI can help distinguish EEE from herpes simplex encephalitis.[13] Computed tomography (CT) may also reveal basal ganglia abnormalities, but MRI is considered more sensitive for detecting characteristic changes.[13]

At present, no antiviral therapy has demonstrated efficacy in the management of EEE. Supportive care remains the cornerstone of treatment, often necessitating intensive care unit admission with ventilatory support.[5] Patient isolation is not required. In individuals with progressive encephalitis, routine monitoring of intracranial pressure and institution of pressure-directed therapies may be indicated. Decompressive craniotomy has been described in refractory cases. Anecdotal reports suggest poorer outcomes with corticosteroid use, whereas limited case reports have indicated possible benefit from immunoglobulin therapy.[17] Because no licensed vaccine is available for human use, prevention is the primary strategy for controlling this infection. Public health measures focus on vector control through reduction of mosquito breeding sites and application of insecticides. At the individual level, personal protective behaviors—including the use of insect repellents and protective clothing—remain essential to minimize risk of exposure.

In regions where EEEV transmission is known to occur, clinicians should maintain a high index of suspicion for EEE in any patient presenting with aseptic meningitis or encephalitis. Additionally, all suspected cases should be promptly reported to the local health department for public health surveillance and response. The differential diagnosis for EEE includes a broad range of viral encephalitides, particularly herpes simplex virus, varicella-zoster virus, enteroviruses (eg, echoviruses), measles, mumps, and arboviruses, eg, West Nile virus or Japanese encephalitis virus. In rare instances, nonviral etiologies, eg, prion disease, including Creutzfeldt–Jakob disease, may also be considered in the differential.[13]

Currently, licensed vaccines against EEEV are available only for veterinary use in horses, with no human vaccine. An inactivated EEEV vaccine has been administered under Investigational New Drug protocols to protect laboratory workers, but it remains unavailable commercially. More recently, a trivalent Modified Vaccinia Ankara (MVA-BN WEV) vaccine targeting EEEV, VEEV, and WEEV demonstrated safety and immunogenicity in phase 1 trials and has progressed to phase 2.[18] Preclinical MVA-based constructs have also provided complete protection against lethal EEEV challenge in animal models.[19]

Eastern equine encephalitis carries a case-fatality rate as high as 41%, with most deaths occurring within the first 2 to 10 days of illness.[CDC.Clinical Signs and Symptoms of Eastern Equine Encephalitis.May 15, 2024] Among survivors, approximately half develop long-term neurologic sequelae, including epilepsy, motor deficits, cognitive impairment, and behavioral disturbances. Recent reports suggest that severe hyponatremia, marked cerebrospinal fluid pleocytosis, and depressed electroencephalogram activity are poor prognostic indicators, likely reflecting heightened neuroinflammation.[11] Corticosteroid therapy has been associated with worse neurologic outcomes, while anecdotal use of intravenous immunoglobulin has been reported, though evidence remains limited.[11] Overall, long-term disability is common, highlighting the importance of supportive management and preventive strategies.

Complications most frequently involve the central nervous system, resulting in lasting cognitive, motor, or sensory deficits. Among survivors, seizures are the most common sequelae, reported in up to 63% of cases, followed by paralysis, intellectual disability, and behavioral disturbances.[20][21] Psychiatric manifestations, including psychosis, have also been described.[22] In severe presentations, delayed recognition and intervention can contribute to autonomic instability, multiorgan failure, and ultimately death. Rare systemic complications have been reported, eg, hemophagocytic lymphohistiocytosis in a 5-month-old infant.[23]

Infection with EEEV occurs through the bite of infected mosquitoes, particularly those inhabiting freshwater swamp environments. Clinical manifestations begin with nonspecific symptoms, eg, fever, chills, headache, myalgias, and arthralgias. Diagnosis relies on serologic testing or detection of viral RNA by PCR from cerebrospinal fluid obtained via lumbar puncture. At present, management is limited to supportive care and close monitoring. The disease carries a case-fatality rate as high as 41%, and up to half of survivors experience long-term neurologic sequelae, including seizures, paralysis, psychosis, or intellectual disability. Because no licensed vaccine is available, prevention through mosquito avoidance remains the most effective strategy. The Centers for Disease Control and Prevention (CDC) recommends the use of Environmental Protection Agency–registered repellents containing DEET, picaridin, IR3535, oil of lemon eucalyptus, para-menthane-diol, or 2-undecanone. Additional measures include wearing long-sleeved shirts and long pants when outdoors, ensuring window and door screens are intact, eliminating standing water around homes, and applying mosquito-control methods both indoors and outdoors. Public education regarding these strategies is critical to reduce the risk of exposure in endemic areas.

Key factors that should be kept in mind when managing EEE include: Clinical Pearl: Eastern equine encephalitis should be suspected in patients with rapidly progressive encephalitis, particularly in endemic areas during mosquito season. Early recognition is critical, as mortality may reach 41% and half of survivors are left with neurologic sequelae. Disposition: Most patients require admission to an intensive care unit for airway protection, seizure control, and intracranial pressure monitoring. Survivors benefit from early initiation of rehabilitation services, including physical, occupational, and neurocognitive therapy. Pitfalls: A common diagnostic pitfall is attributing early symptoms to benign viral syndromes, which may delay lumbar puncture, neuroimaging, or reporting to public health authorities. Another frequent error is over-reliance on a single negative PCR or serology result, since early testing may be falsely negative. Repeated sampling and integration of epidemiologic context are essential. Prevention: With no available human vaccine, the cornerstone of prevention is mosquito avoidance and vector control. Clinicians should counsel patients on the use of EPA-registered repellents (DEET, picaridin, IR3535, oil of lemon eucalyptus, para-menthane-diol, 2-undecanone), protective clothing, and elimination of standing water near homes.

EEE is a rare but severe arboviral infection in the Americas, characterized by a high case-fatality rate and significant long-term neurologic sequelae among survivors. The virus, transmitted primarily through mosquito-bird cycles, can sporadically infect humans, presenting initially with nonspecific symptoms such as fever, headache, and malaise. A small proportion of patients progress to encephalitis, marked by altered mental status, seizures, and focal neurologic deficits. Diagnosis relies on serial serologic testing, PCR, and neuroimaging, while management remains primarily supportive, emphasizing intensive monitoring and prevention of complications. Public health strategies, including vector control and personal protective measures, are essential to reduce exposure and disease incidence. Effective management of EEE requires coordinated interprofessional collaboration. Physicians and advanced practitioners must recognize early signs and engage neurology consultation when indicated, while nurses provide vigilant monitoring and family support. Pharmacists optimize supportive therapies and ensure medication safety. Timely communication with epidemiologists and health departments facilitates outbreak detection and prevention. Through shared responsibility, coordinated care, and ongoing interprofessional communication, healthcare teams enhance patient-centered care, improve outcomes, maintain safety, and strengthen community-level prevention efforts.